Strategic Global Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Strategic Global Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,367	Closed	-$4.45M	–	159
2022 Q1	$4.45M	Buy	6,367 +310	+5%	+$196K	0.65%	53
2021 Q4	$3.83M	Buy	6,057 +762	+14%	+$469K	0.49%	70
2021 Q3	$3.2M	Buy	5,295 +1,263	+31%	+$784K	0.47%	72
2021 Q2	$2.25M	Sell	4,032 -462	-10%	-$234K	0.41%	87
2021 Q1	$2.13M	Buy	4,494 +2,678	+147%	+$1.3M	0.38%	95
2020 Q4	$877K	Sell	1,816 -25	-1%	-$13.5K	0.15%	124
2020 Q3	$1.03M	Buy	+1,841	New	+$1.12M	0.19%	113

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Strategic Global Advisors's REGN Position: Q2 2022 in Review

Strategic Global Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 6,367 shares — an estimated $4.45M sold.

Strategic Global Advisors first reported a position in REGN in Q3 2020 and held it in 7 quarters. The position peaked at $4.45M in Q1 2022. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

Strategic Global Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Strategic Global Advisors sold 6,367 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $4.45M.
Strategic Global Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 7 quarters.
Strategic Global Advisors's Regeneron Pharmaceuticals position peaked at $4.45M in Q1 2022.
1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Strategic Global Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.